Margarida Azevedo,  —

Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. The move follows the FDA’s granting of fast track designation to the…

Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma lived without disease progression, compared with Revlimid and dexamethasone alone, topline data from a Phase 3 clinical trial showed. While the ELOQUENT-1 trial (NCT01335399),…

Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The data will include recent evaluations of the drugs Blincyto (blinatumomab), Kyprolis (carfilzomib), Aranesp (darbepoetin alfa) and Nplate (romiplostim) in treating a range of malignancies, such as multiple…

Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with relapsed or refractory multiple myeloma, compared to lenalidomide and dexamethasone alone. The ongoing trial met its primary endpoint, with treated patients demonstrating improved progression-free survival, indicating that the…

Ajai Chari, MD, director of clinical research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai in New York, and Navneet Majhail, MD, MS, director of the Blood & Marrow Transplant Program at Cleveland Clinic, recently shared their views and analyses of two studies investigating the role and…

Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of body size or smoking history, indicating that it is essential to educate inactive adults of the benefits of physical activity, with an emphasis on its influence…

Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma, which will hopefully allow researchers to better understand the pathology and physiology involved in the development of the disease and test new potential therapeutic agents. The…

Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of monoclonal protein, but did not cause cell death. The study was presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New…

A research team led by William Matsui, MD, and Carol Ann Huff, MD, with the Johns Hopkins Kimmel Cancer Center, has found that MedImmune’s novel MEDI-551 antibody treatment effectively decreased the number of cancer stem cells, which drive the growth of cancer, in most patients with recently diagnosed multiple myeloma. Study results will be…